Comorbid Conditions: EDS-MCAS-ME/CFS Triad
1 EDS–MCAS Genetic and Pathophysiological Basis
Principal Investigator:: Multiple groups
Institution:: Multi-centre (international)
Contact/URL:: PMID 41554340 (2026 review); PMID 39451569 (2024 genetics)
Funder:: Institutional
Status:: Published 2024–2026
Phase:: Review and genetic analysis
Cohort:: hEDS patients + controls (genetics: \(n \approx 250\))
Mechanism/Focus:: Two convergent lines of research: (1) a 2026 review examining pathophysiological and clinical links between EDS and MCAS, highlighting bidirectional fibroblast–mast cell interactions in the extracellular matrix; (2) a 2024 genetic study identifying variants in MT-CYB, HTT, MUC3A, HLA-B, and HLA-DRB1 implicated in hEDS and mast cell hypersensitivity (72.2% of hEDS cohort vs 14.2% controls).
Primary Outcomes:: Genetic basis for the EDS–MCAS overlap; pathophysiological framework for the clinical triad
Estimated Completion:: Published
Document Relevance:: Ch. 7 (immune dysfunction—mast cells), Ch. 10 (cardiovascular—connective tissue), Ch. 14 Speculative Cross-Disease Connections (comorbidity patterns)
The EDS–MCAS–ME/CFS triad is one of the most clinically recognisable comorbidity patterns, yet its biological basis has been poorly understood (2026) (2024). The fibroblast–mast cell interaction framework provides a mechanistic link: abnormal collagen (EDS) alters the extracellular matrix, which modulates mast cell behaviour (MCAS), which drives systemic immune activation (ME/CFS). The HLA associations suggest an autoimmune component that connects to the broader autoantibody research in Sections Autoimmunity and Immunomodulation–Autoimmunity and Immunomodulation.